Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(7), P. 1916 - 1916

Published: July 10, 2023

Artificial intelligence (AI) has emerged as a powerful tool that harnesses anthropomorphic knowledge and provides expedited solutions to complex challenges. Remarkable advancements in AI technology machine learning present transformative opportunity the drug discovery, formulation, testing of pharmaceutical dosage forms. By utilizing algorithms analyze extensive biological data, including genomics proteomics, researchers can identify disease-associated targets predict their interactions with potential candidates. This enables more efficient targeted approach thereby increasing likelihood successful approvals. Furthermore, contribute reducing development costs by optimizing research processes. Machine assist experimental design pharmacokinetics toxicity capability prioritization optimization lead compounds, need for costly animal testing. Personalized medicine approaches be facilitated through real-world patient leading effective treatment outcomes improved adherence. comprehensive review explores wide-ranging applications delivery form designs, process optimization, testing, pharmacokinetics/pharmacodynamics (PK/PD) studies. an overview various AI-based utilized technology, highlighting benefits drawbacks. Nevertheless, continued investment exploration industry offer exciting prospects enhancing processes care.

Language: Английский

---

Advances in nanotechnology versus stem cell therapy for the theranostics of Huntington's disease

Journal of Drug Delivery Science and Technology, Journal Year: 2023, Volume and Issue: 87, P. 104774 - 104774

Published: July 20, 2023

Huntington's disease (HD) is a neurological disorder characterized by reduction in medium-spiny neurons the brain. Currently, there no cure for HD and treatment relies on symptomatic therapy. The generation of stem cells, including neural, mesenchymal, pluripotent, through conventional strategies or direct cell reprogramming has revolutionized therapy research. Due to their unique ability differentiate into variety self-renew, grow, cells have become an area interest treating various complex unresolved neurodegenerative disorders. Nanotechnology emerged as novel approach with great potential reduced side effects. Nanoparticles (NPs) can act nanovehicles delivering therapeutic agents, siRNAs, neurotrophic factors, different drugs. Additionally, NPs be used alternative based antioxidant reactive oxygen species (ROS)-scavenging properties that protect neuronal cells. Some even exhibit interfere protein aggregation mutant Huntingtin proteins during processes. This review focuses most studied HD, polymeric, lipid-based, liposomes, solid lipid metal/metal oxide. combination diagnosis treatment. been manage cellular microenvironment, improve efficiency drug delivery brain enhance transplant survival. Understanding characteristics essential applying them purposes. In this study, biology well benefits drawbacks using its are discussed.

Language: Английский

---

CAR-T cell therapy: Where are we now, and where are we heading?

Blood Science, Journal Year: 2023, Volume and Issue: 5(4), P. 237 - 248

Published: Oct. 1, 2023

Chimeric antigen receptor (CAR)-T-cell therapies have exhibited remarkable efficacy in the treatment of hematologic malignancies, with 9 CAR-T-cell products currently available. Furthermore, CAR-T cells shown promising potential for expanding their therapeutic applications to diverse areas, including solid tumors, myocardial fibrosis, and autoimmune infectious diseases. Despite these advancements, significant challenges pertaining treatment-related toxic reactions relapses persist. Consequently, current research efforts are focused on addressing issues enhance safety reduce relapse rate. This article provides a comprehensive overview present state therapies, achievements, existing challenges, future developments.

Language: Английский

---

Antitumor Research Based on Drug Delivery Carriers: Reversing the Polarization of Tumor-Associated Macrophages

Molecular Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 27, 2025

The development of malignant tumors is a complex process that involves the tumor microenvironment (TME). An immunosuppressive TME presents significant challenges to current cancer therapies, serving as key mechanism through which cells evade immune detection and play crucial role in progression metastasis. This impedes optimal effectiveness immunotherapeutic approaches, including cytokines, checkpoint inhibitors, vaccines. Tumor-associated macrophages (TAMs), major component tumor-infiltrating cells, exhibit dual functionalities: M1-like TAMs suppress tumorigenesis, while M2-like promote growth Consequently, various nanocarriers aimed at polarizing phenotypes distinct mechanisms has emerged promising therapeutic strategy inhibit escape enhance antitumor responses. Review covers origin types TAMs, common pathways regulating macrophage polarization, progression, strategies targeting aiming provide comprehensive understanding guidance for future research clinical applications.

Language: Английский

---

Lactic acid: The culprit behind the immunosuppressive microenvironment in hepatocellular carcinoma

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2024, Volume and Issue: 1879(5), P. 189164 - 189164

Published: Aug. 2, 2024

Language: Английский

---

Pirtobrutinib in Chinese patients with relapsed or refractory B‐cell malignancies: A single‐arm, open‐label, phase 2, multicenter trial

International Journal of Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 28, 2025

Abstract Pirtobrutinib, a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi), demonstrated clinically meaningful antitumor responses in covalent BTKi pretreated mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) or small (SLL) the global phase 1/2 BRUIN study. In this multi‐center, open‐label, 2 trial, we investigated efficacy safety of pirtobrutinib Chinese patients with relapsed/refractory (R/R) MCL, CLL/SLL, other B‐cell malignancies. All received once daily continuous 28‐day cycles. The primary endpoint was overall response rate (ORR). Efficacy assessed MCL CLL/SLL prior treatment all enrolled who at least one dose pirtobrutinib. Among 35 BTKis (cBTKi) ORR 62.9% (95% CI: 44.9, 78.5), median duration (DOR) not reached, 12‐month DOR 59.7% 35.3, 77.5). 11 cBTKi 63.6% 30.8, 89.1), 83.3% 27.3, 97.5). most common adverse events population ( n = 87) were anemia (32.2%) neutrophil count decreased (31.0%). Grade ≥3 hemorrhage occurred 2.3% there no cases atrial fibrillation/flutter. Pirtobrutinib R/R preliminary activity generally well‐tolerated new signals observed.

Language: Английский

---

Advanced Artificial Intelligence Technologies Transforming Contemporary Pharmaceutical Research

Bioengineering, Journal Year: 2025, Volume and Issue: 12(4), P. 363 - 363

Published: March 31, 2025

One area of study within machine learning and artificial intelligence (AI) seeks to create computer programs with that can mimic human focal processes in order produce results. This technique includes data collection, effective usage system development, conclusion illustration, arrangements. Analysis algorithms are cognitive activities the most widespread application AI. Artificial studies have proliferated, field is quickly beginning understand its potential impact on medical services investigation. review delves deeper into pros cons AI across healthcare pharmaceutical research industries. Research articles published throughout last few years were selected from PubMed, Google Scholar, Science Direct, using search terms like ‘artificial intelligence’, ‘drug discovery’, ‘pharmacy research’, ‘clinical trial’, etc. article provides a comprehensive overview how being used diagnose diseases, treat patients digitally, find new drugs, predict when outbreaks or pandemics may occur. In intelligence, neural networks deep some popular tools; clinical research, Bayesian non-parametric approaches hold promise for better results, while smartphones processing natural languages employed recognizing trial monitoring. Seasonal flu, Ebola, Zika, COVID-19, tuberculosis, outbreak predictions made computation intelligence. The academic world hopeful development will lead more efficient less expensive investigations public services.

Language: Английский

---

Pre-infusion 18F-FDG PET/CT for Prognostic and Toxicity Prediction in B-cell Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-cell Therapy

Clinical Nuclear Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 7, 2025

Purpose: The aim of this study was to evaluate the value 18 F-FDG PET/CT in predicting outcomes and toxicity for patients with B-cell non-Hodgkin lymphoma (B-NHL) who underwent chimeric antigen receptor T (CAR-T) cell therapy. Methods: This retrospective included B-NHL CAR-T therapy had pre-infusion images. We recorded SUVmax, metabolic tumor volume (MTV), total lesion glycolysis (TLG), various clinical laboratory indexes. primary endpoints were progression-free survival (PFS) overall (OS). PFS OS estimated using Kaplan-Meier method. In addition, we reported correlation between parameters objective response (OR), as well cytokine release syndrome (CRS). Results: A 133 enrolled study. median follow-up duration 20.8 months. SUVmax (with a cutoff 15.65) emerged an independent parameter associated PFS, OS, OR. Patients ≥15.65 9.13 months (95% CI: 0.11–18.16), while those SUVmax<15.65 not reached ( P =0.006). Furthermore, exhibited significantly shorter average compared (26.89 mo vs. 45.14 mo, =0.010). odds ratio achieving OR found be lower at 0.173 0.056–0.539). Other factors ECOG-PS, B symptoms, bulky mass, extranodal sites, whereas IPI LDH OS. Deauville scores showed weak positive occurrence CRS. Conclusions: pretreatment appears promising predictive factor efficacy prognosis, being Consequently, can conclude that from scans may serve valuable tool guiding patient selection potential side effects.

Language: Английский

---

How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives

Bone Marrow Transplantation, Journal Year: 2025, Volume and Issue: unknown

Published: April 14, 2025

Cellular therapies have been cornerstones of the treatment mantle cell lymphoma (MCL) for decades and helped to improve outcome this formerly very unfavourable B-cell considerably. Current established roles cellular include autologous hematopoietic transplantation (HCT) as part first-line therapy, chimeric antigen receptor-engineered T-cells (CART) relapsed/refractory MCL, allogeneic HCT settings in which CARTs failed or are unavailable. Therapeutic innovations recently entered MCL landscape moving upstream algorithms, challenging existing management principles. The purpose paper is give some guidance regarding how best use increasingly complex environment. Due differences CART labels, available non-cellular options, philosophy between American European health systems, we found it reasonable contrast perspectives on defined standard scenarios, often overlapping but show discrepancies important aspects.

Language: Английский

---

Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma

Annals of Hematology, Journal Year: 2025, Volume and Issue: unknown

Published: April 25, 2025

To characterise the effectiveness of Bruton tyrosine kinase inhibitors with venetoclax in patients refractory or relapsed mantle cell lymphoma, without addition an anti-CD20 antibody. Progression-free and overall survival were estimated for forty-nine treated (200 mg, daily) combination monoclonal antibody between June 2018 February 2022 China. The median number treatment lines before therapy was three (range, 2-7). patient age 62 years, a male-to-female ratio 3.08:1. Patients exhibited high-risk features including Ki-67 ≥ 30% (89.8%), blastoid/pleomorphic histology (36.7%), lymphoma International Prognostic Index group (42.9%), complex karyotype (27.7%), TP53 mutations (71.4%), combined other gene KMT2D, NSD2, CCND1, NOTCH1, CDKN2A, NOTCH2 SMARCA4 (57.1%), progression disease within 24 months (65.3%), similar efficacy prognosis to low-risk cases. Basic clinical cytogenetic characteristics, as well survival, dual triple groups (all p > 0.05). optimal response complete remission rates 67.4% 53.1%, respectively. 3-year progression-free 37.5% 50.8%, Eastern Cooperative Oncology Group≥2was independent predictor survival. Group performance status 2, mutationswere factors poor most common adverse reactions haematological pulmonary infections. leading cause death (19/22). venetoclax, demonstrated good particularly early treatment. There no advantages adding CD20 antibodies. ultrahigh-risk required more aggressive treatments.

Language: Английский

---